Patents by Inventor Daniel J. Pippel

Daniel J. Pippel has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • DISUBSTITUTED OCTAHYDROPYRROLO[3,4-C]PYRROLES AS OREXIN RECEPTOR MODULATORS
    Publication number: 20240109901
    Abstract: Disubstituted octahydropyrrolo[3,4-c]pyrrole compounds are described, which are useful as orexin receptor modulators. Such compounds may be useful in pharmaceutical compositions and methods for the treatment of diseased states, disorders, and conditions mediated by orexin activity, such as insomnia.
    Type: Application
    Filed: June 2, 2023
    Publication date: April 4, 2024
    Inventors: Wenying Chai, Michael A. Letavic, Kiev S. Ly, Daniel J. Pippel, Dale A. Rudolph, Kathleen C. Sappey, Brad M. Savall, Chandravadan R. Shah, Brock T. Shireman, Akinola Soyode Johnson, Emily M. Stocking, Devin M. Swanson
  • Small molecule inhibitors of NF-kB inducing kinase
    Patent number: 11827634
    Abstract: The present invention relates to compounds that inhibit NIK and pharmaceutical compositions comprising such compounds and methods of using the same. These compounds and pharmaceutical compositions are envisaged to be useful for preventing or treating diseases such as cancer (such as B-cell malignancies including leukemias, lymphomas and myeloma), inflammatory disorders, autoimmune disorders, immunodermatologic disorders such as palmoplantar pustulosis and hidradenitis suppurativa, and metabolic disorders such as obesity and diabetes.
    Type: Grant
    Filed: December 13, 2021
    Date of Patent: November 28, 2023
    Assignee: Janssen Pharmaceutica NV
    Inventors: Wendy Eccles, Michael D. Hack, William M. Jones, Paul J. Krawczuk, Alec D. Lebsack, Daniel J. Pippel, Alexander R. Rovira, Ronald L. Wolin
  • Disubstituted octahydropyrrolo[3,4-c]pyrroles as orexin receptor modulators
    Patent number: 11667644
    Abstract: Disubstituted octahydropyrrolo[3,4-c]pyrrole compounds are described, which are useful as orexin receptor modulators. Such compounds may be useful in pharmaceutical compositions and methods for the treatment of diseased states, disorders, and conditions mediated by orexin activity, such as insomnia.
    Type: Grant
    Filed: July 9, 2021
    Date of Patent: June 6, 2023
    Assignee: Janssen Pharmaceutica NV
    Inventors: Wenying Chai, Michael A. Letavic, Kiev S. Ly, Daniel J. Pippel, Dale A. Rudolph, Kathleen C. Sappey, Brad M. Savall, Chandravadan R. Shah, Brock T. Shireman, Akinola Soyode Johnson, Emily M. Stocking, Devin M. Swanson
  • SMALL MOLECULE INHIBITORS OF NF-kB INDUCING KINASE
    Publication number: 20230080834
    Abstract: The present invention relates to compounds that inhibit NIK and pharmaceutical compositions comprising such compounds and methods of using the same. These compounds and pharmaceutical compositions are envisaged to be useful for preventing or treating diseases such as cancer (such as B-cell malignancies including leukemias, lymphomas and myeloma), inflammatory disorders, autoimmune disorders, immunodermatologic disorders such as palmoplantar pustulosis and hidradenitis suppurativa, and metabolic disorders such as obesity and diabetes.
    Type: Application
    Filed: December 13, 2021
    Publication date: March 16, 2023
    Inventors: Wendy Eccles, Michael D. Hack, William M. Jones, Paul J. Krawczuk, Alec D. Lebsack, Daniel J. Pippel, Alexander R. Rovira, Ronald L. Wolin
  • Small molecule inhibitors of NF-?B inducing kinase
    Patent number: 11254673
    Abstract: The present invention relates to compounds that inhibit NIK and pharmaceutical compositions comprising such compounds and methods of using the same. These compounds and pharmaceutical compositions are envisaged to be useful for preventing or treating diseases such as cancer (such as B-cell malignancies including leukemias, lymphomas and myeloma), inflammatory disorders, autoimmune disorders, immunodermatologic disorders such as palmoplantar pustulosis and hidradenitis suppurativa, and metabolic disorders such as obesity and diabetes.
    Type: Grant
    Filed: May 29, 2020
    Date of Patent: February 22, 2022
    Assignee: Janssen Pharmaceutica NV
    Inventors: J. Kent Barbay, Wenying Chai, Wendy Eccles, Michael D. Hack, Aaron T. Herrmann, William M. Jones, Paul J. Krawczuk, Kevin D. Kreutter, Alec D. Lebsack, Daniel J. Pippel, Alexander R. Rovira, Ronald L. Wolin
  • Disubstituted Octahydropyrrolo[3,4-c]Pyrroles As Orexin Receptor Modulators
    Publication number: 20210347781
    Abstract: Disubstituted octahydropyrrolo[3,4-c]pyrrole compounds are described, which are useful as orexin receptor modulators. Such compounds may be useful in pharmaceutical compositions and methods for the treatment of diseased states, disorders, and conditions mediated by orexin activity, such as insomnia.
    Type: Application
    Filed: July 9, 2021
    Publication date: November 11, 2021
    Inventors: Wenying Chai, Michael A. Letavic, Kiev S. Ly, Daniel J. Pippel, Dale A. Rudolph, Kathleen C. Sappey, Brad M. Savall, Chandravadan R. Shah, Brock T. Shireman, Akinola Soyode Johnson, Emily M. Stocking, Devin M. Swanson
  • SMALL MOLECULE INHIBITORS OF NF-kB INDUCING KINASE
    Publication number: 20210300918
    Abstract: The present invention relates to compounds that inhibit NIK and pharmaceutical compositions comprising such compounds and methods of using the same. These compounds and pharmaceutical compositions are envisaged to be useful for preventing or treating diseases such as cancer (such as B-cell malignancies including leukemias, lymphomas and myeloma), inflammatory disorders, autoimmune disorders, immunodermatologic disorders such as palmoplantar pustulosis and hidradenitis suppurativa, and metabolic disorders such as obesity and diabetes.
    Type: Application
    Filed: May 29, 2020
    Publication date: September 30, 2021
    Inventors: J. Kent Barbay, Wenying Chai, Wendy Eccles, Michael D. Hack, Aaron T. Herrmann, William M. Jones, Paul J. Krawczuk, Kevin D. Kreutter, Alec D. Lebsack, Daniel J. Pippel, Alexander R. Rovira, Ronald L. Wolin
  • Disubstituted octahydropyrrolo[3,4-C]pyrroles as orexin receptor modulators
    Patent number: 11059828
    Abstract: Disubstituted octahydropyrrolo[3,4-c]pyrrole compounds are described, which are useful as orexin receptor modulators. Such compounds may be useful in pharmaceutical compositions and methods for the treatment of diseased states, disorders, and conditions mediated by orexin activity, such as insomnia.
    Type: Grant
    Filed: October 15, 2019
    Date of Patent: July 13, 2021
    Assignee: Janssen Pharmaceutica NV
    Inventors: Wenying Chai, Michael A. Letavic, Kiev S. Ly, Daniel J. Pippel, Dale A. Rudolph, Kathleen C. Sappey, Brad M. Savall, Chandravadan R. Shah, Brock T. Shireman, Akinola Soyode Johnson, Emily M. Stocking, Devin M. Swanson
  • Disubstituted Octahydropyrrolo[3,4-C]Pyrroles As Orexin Receptor Modulators
    Publication number: 20200048263
    Abstract: Disubstituted octahydropyrrolo[3,4-c]pyrrole compounds are described, which are useful as orexin receptor modulators. Such compounds may be useful in pharmaceutical compositions and methods for the treatment of diseased states, disorders, and conditions mediated by orexin activity, such as insomnia.
    Type: Application
    Filed: October 15, 2019
    Publication date: February 13, 2020
    Inventors: Wenying Chai, Michael A. Letavic, Kiev S. Ly, Daniel J. Pippel, Dale A. Rudolph, Kathleen C. Sappey, Brad M. Savall, Chandravadan R. Shah, Brock T. Shireman, Akinola Soyode Johnson, Emily M. Stocking, Devin M. Swanson
  • Process for the preparation of histamine H3 receptor modulators
    Patent number: 10323002
    Abstract: The present invention is directed to novel processes for the preparation of histamine H3 receptor modulators, in the treatment of for example, cognitive disorders, sleep disorders and/or psychiatric disorders.
    Type: Grant
    Filed: October 4, 2017
    Date of Patent: June 18, 2019
    Assignee: Janssen Pharmaceutica NV
    Inventors: Diego Fernando Domenico Broggini, Vit Lellek, Susanne Lochner, Neelakandha S. Mani, Adrian Maurer, Daniel J. Pippel, Lana K. Young
  • FLAP modulators
    Patent number: 9884878
    Abstract: The present invention relates to compounds of Formula (I), or a form thereof, wherein ring A, R1, R2, R3, R3?, L, W, and V are as defined herein, useful as FLAP modulators. The invention also relates to pharmaceutical compositions comprising compounds of Formula (I). Methods of making and using the compounds of Formula (I) are also within the scope of the invention.
    Type: Grant
    Filed: June 2, 2015
    Date of Patent: February 6, 2018
    Assignee: JANSSEN PHARMACEUTICA NV
    Inventors: Genesis M. Bacani, Wendy Eccles, Anne E. Fitzgerald, Steven D. Goldberg, Michael D. Hack, Natalie A. Hawryluk, William M. Jones, John M. Keith, Paul Krawczuk, Alec D. Lebsack, Alice Lee-Dutra, Jing Liu, Kelly J. McClure, Steven P. Meduna, Daniel J. Pippel, Mark D. Rosen, Zachary S. Sales
  • PROCESS FOR THE PREPARATION OF HISTAMINE H3 RECEPTOR MODULATORS
    Publication number: 20180022704
    Abstract: The present invention is directed to novel processes for the preparation of histamine H3 receptor modulators, in the treatment of for example, cognitive disorders, sleep disorders and/or psychiatric disorders.
    Type: Application
    Filed: October 4, 2017
    Publication date: January 25, 2018
    Applicant: Janssen Pharmaceutica NV
    Inventors: Diego Fernando Domenico BROGGINI, Vit LELLEK, Susanne LOCHNER, Neelakandha S. MANI, Adrian MAURER, Daniel J. PIPPEL, Lana K. YOUNG
  • Process for the preparation of histamine H3 receptor modulators
    Patent number: 9809547
    Abstract: The present invention is directed to novel processes for the preparation of histamine H3 receptor modulators, in the treatment of for example, cognitive disorders, sleep disorders and/or psychiatric disorders.
    Type: Grant
    Filed: November 11, 2016
    Date of Patent: November 7, 2017
    Assignee: Janssen Pharmaceutica NV
    Inventors: Diego Fernando Domenico Broggini, Vit Lellek, Susanne Lochner, Neelakandha S. Mani, Adrian Maurer, Daniel J. Pippel, Lana K. Young
  • Flap modulators
    Patent number: 9745328
    Abstract: The present invention relates to compounds of Formula (I), or a form thereof wherein ring A1, R1, R2, R3, R3?, L, W, and V are as defined herein, useful as FLAP modulators. The invention also relates to pharmaceutical compositions comprising compounds of Formula (I). Methods of making and using the compounds of Formula (I) are also within the scope of the invention.
    Type: Grant
    Filed: January 31, 2014
    Date of Patent: August 29, 2017
    Assignee: Janssen Pharmaceutica NV
    Inventors: Genesis M. Bacani, Wendy Eccles, Anne E. Fitzgerald, Steven D. Goldberg, Michael D. Hack, Natalie A. Hawryluk, William M. Jones, John M. Keith, Paul Krawczuk, Alec D. Lebsack, Alice Lee-Dutra, Jing Liu, Kelly J. McClure, Steven P. Meduna, Daniel J. Pippel, Mark D. Rosen, Zachary S. Sales
  • 1,2,6-substituted benzimidazoles as flap modulators
    Patent number: 9695149
    Abstract: The present invention relates to compounds of Formula (I), and solvates, hydrates, and pharmaceutically acceptable salts thereof, wherein X1, X1?, X1?, R1, R2 and R3 are as defined herein, useful as FLAP modulators. The invention also relates to pharmaceutical compositions comprising compounds of Formula (I). Methods of making and using the compounds of Formula (I) are also within the scope of the invention.
    Type: Grant
    Filed: March 13, 2014
    Date of Patent: July 4, 2017
    Assignee: JANSSEN PHARMACEUTICA NV
    Inventors: Wenying Chai, Curt A. Dvorak, Wendy Eccles, James P. Edwards, Steven D. Goldberg, Paul J. Krawczuk, Alec D. Lebsack, Jing Liu, Daniel J. Pippel, Zachary S. Sales, Virginia M. Tanis, Mark S. Tichenor, John J. M. Wiener
  • Disubstituted Octahydropyrrolo[3,4-C]Pyrroles As Orexin Receptor Modulators
    Publication number: 20170129901
    Abstract: Disubstituted octahydropyrrolo[3,4-c]pyrrole compounds are described, which are useful as orexin receptor modulators. Such compounds may be useful in pharmaceutical compositions and methods for the treatment of diseased states, disorders, and conditions mediated by orexin activity, such as insomnia.
    Type: Application
    Filed: January 24, 2017
    Publication date: May 11, 2017
    Inventors: Wenying Chai, Michael A. Letavic, Kiev S. Ly, Daniel J. Pippel, Dale A. Rudolph, Kathleen C. Sappey, Brad M. Savall, Chandravadan R. Shah, Brock T. Shireman, Akinola Soyode Johnson, Emily M. Stocking, Devin M. Swanson
  • PROCESS FOR THE PREPARATION OF HISTAMINE H3 RECEPTOR MODULATORS
    Publication number: 20170057919
    Abstract: The present invention is directed to novel processes for the preparation of histamine H3 receptor modulators, in the treatment of for example, cognitive disorders, sleep disorders and/or psychiatric disorders.
    Type: Application
    Filed: November 11, 2016
    Publication date: March 2, 2017
    Applicant: Janssen Pharmaceutica NV
    Inventors: Diego Fernando Domenico BROGGINI, Vit LELLEK, Susanne LOCHNER, Neelakandha S. MANI, Adrian MAURER, Daniel J. PIPPEL, Lana K. YOUNG
  • Process for the preparation of histamine H3 receptor modulators
    Patent number: 9518021
    Abstract: The present invention is directed to novel processes for the preparation of histamine H3 receptor modulators, in the treatment of for example, cognitive disorders, sleep disorders and/or psychiatric disorders.
    Type: Grant
    Filed: April 25, 2014
    Date of Patent: December 13, 2016
    Assignee: JANSSEN PHARMACEUTICA NV
    Inventors: Diego Broggini, Vit Lellek, Susanne Lochner, Neelakandha S. Mani, Adrian Maurer, Daniel J. Pippel, Lana K. Young
  • Benzoimidazol-2-yl pyrimidine derivatives
    Patent number: 9371311
    Abstract: The present invention is directed to benzoimidazol-2-yl pyrimidine derivatives useful as histamine H4 receptor modulators and processes for the preparation of such compounds.
    Type: Grant
    Filed: August 14, 2014
    Date of Patent: June 21, 2016
    Assignee: Janssen Pharmaceutica NV
    Inventors: Neelakandha S. Mani, Christopher L. Mapes, Daniel J. Pippel, Diego F. Broggini
  • Disubstituted octahydropyrrolo[3,4-c]pyrroles as orexin receptor modulators
    Patent number: RE48841
    Abstract: Disubstituted octahydropyrrolo[3,4-c]pyrrole compounds are described, which are useful as orexin receptor modulators. Such compounds may be useful in pharmaceutical compositions and methods for the treatment of diseased states, disorders, and conditions mediated by orexin activity, such as insomnia.
    Type: Grant
    Filed: April 23, 2019
    Date of Patent: December 7, 2021
    Assignee: Janssen Pharmaceutica NV
    Inventors: Wenying Chai, Michael A. Letavic, Kiev S. Ly, Daniel J. Pippel, Dale A. Rudolph, Kathleen C. Sappey, Brad M. Savall, Chandravadan R. Shah, Brock T. Shireman, Akinola Soyode-Johnson, Emily M. Stocking, Devin M. Swanson